FDA approves Acceleron's blood disorder drug ahead of schedule

Luspatercept is one of the first treatments for beta thalassemia, a blood disorder being targeted by multiple local companies.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.